Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome

Quoin Pharmaceuticals Ltd., a clinical stage specialty pharmaceutical company focused on rare and orphan diseases,  announced that it will expand its ongoing Netherton Syndrome clinical studies to include international sites. The first international site will be opened at a research hospital in Saudi Arabia. This hospital is currently treating a number of Netherton patients who will now become eligible for recruitment into Quoin’s studies. An experienced Clinical Research Organization has been engaged to manage the study locally. The Saudi site will operate under the auspices of Quoin’s open Investigational New Drug (IND) application with the US Food and Drug Administration. Plans to open additional international clinical sites are at an advanced stage.

Quoin CEO, Dr. Michael Myers, said, “We are very pleased to announce this exciting development for our ongoing clinical studies. We hope that the opening of this first international site, which is currently treating Netherton patients, will speed up overall recruitment into our studies whilst expanding the diversity of the patient population being tested. We are working hard to open additional international sites to augment the five sites that are currently open in the US. Quoin is committed to completing recruitment into our clinical studies as expeditiously as possible with a view to potentially delivering the first approved treatment to this underserved patient population.”

Quoin is conducting two ongoing clinical trials evaluating QRX003, a topical lotion, for the treatment of Netherton Syndrome. For more information about the trials, please visit:

Read more here.

Recent News


Capra Biosciences Lands $7.5 Million Project Agreement To Demonstrate Platform To Rapidly Scale Pharmaceutical Ingredient Manufacturing

Many ingredients that make up the pharmaceuticals Americans rely on are manufactured overseas. When supply chain issues or shortages occur, as witnessed during the COVID pandemic, it can negatively impact millions of Americans and affect national security. The White House issued an Executive Order in 2022 to stimulate U.S. biomanufacturing. Increasing American biomanufacturing, will provide


Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity

AMPEL BioSolutions, with collaborators Lupus Therapeutics and Aker Biomarine, revealed peer-reviewed results that supplementation with Omega3-rich Krill Oil improves disease activity of autoimmune Lupus patients. Omega3 lipids called polyunsaturated fatty acids (PUFAs) that are found in microscopic shrimp-like crustaceans called Krill from the waters around Antarctica are key to maintaining a low inflammatory state.  Some


Inorganic Ventures acquires PURE Analytical Laboratories, Combining Unique Capabilities for Precision Manufacturing

Two privately held specialty chemical firms that provide high-purity materials and services for chemical applications, from renewable energy to food and beverages and consumer safety, are combining their capabilities to serve new and expanding precision markets. IV Labs Inc., the parent company of Inorganic Ventures, has acquired PURE Analytical Laboratories, one of the few companies that